Open AccessCombination of Sulindac and Eflornithine Delays the Need for Lower Gastrointestinal Surgery in Patients With Familial Adenomatous Polyposis: Post Hoc Analysis of a Randomized Clinical Trial
Author(s) -
Francesc Balaguer,
Elena M. Stoffel,
Carol A. Burke,
Evelien Dekker,
N. Jewel Samadder,
Éric Van Cutsem,
Patrick M. Lynch,
Paul E. Wise,
Robert Hüneburg,
Ramona M. Lim,
Michelle L. Boytim,
Wei Du,
Elizabeth Bruckheimer,
Alfred M. Cohen,
James M. Church,
F Bmt Trial Investigators
Publication year - 2022
Publication title -
diseases of the colon and rectum
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.575
H-Index - 162
eISSN - 1530-0358
pISSN - 0012-3706
DOI - 10.1097/dcr.0000000000002095
Subject(s) - medicine , sulindac , familial adenomatous polyposis , eflornithine , surgery , gastroenterology , randomized controlled trial , randomization , adenomatous polyposis coli , colorectal cancer , cancer , biochemistry , chemistry , nonsteroidal , enzyme , spermidine
Colectomy and proctocolectomy are the initial standard of care for patients with familial adenomatous polyposis. Pharmacotherapy to prevent the progression of polyposis and surgeries in the lower GI tract would be beneficial to patients with this disease.